ERBB2 and breast cancer: The phase III KRISTINE trial compared neoadjuvant treatments for HER2-positive breast cancer, showing that traditional chemotherapy plus dual HER2-targeted blockade (trastuzumab and pertuzumab) achieved a significantly higher pathological complete response rate than T-DM1 plus pertuzumab, though the latter had fewer grade 3–4 and serious adverse events [69].